Lupus Research Alliance, Inc.

The Lupus Research Alliance (LRA) is a leading American voluntary health organization dedicated to finding better treatments and ultimately preventing and curing systemic lupus erythematosus (SLE or lupus), a debilitating autoimmune disease. Headquartered in New York City, the LRA's core mission is to drive the discovery and development of next-generation lupus diagnostics and curative treatments through innovative research and collaborations.

The organization's primary activities include grant-making management, funding promising research projects, and supporting clinical trials. The LRA has invested over $220 million in lupus research across more than 525 research and clinical studies, making it the world's largest non-governmental, non-profit funder of lupus research. A key component of its operations is Lupus Therapeutics (LT), its clinical affiliate, which coordinates and manages the Lupus Clinical Investigators Network (LuCIN), a North American-based clinical trial consortium. This structure enables the LRA to influence clinical development programs and enhance community participation in clinical trials. Notably, 100% of public donations to the LRA directly support research programs, as its Board of Directors covers all administrative and fundraising costs.

Albert T. Roy serves as the President and CEO of the Lupus Research Alliance, having been appointed to the role in September 2022. The organization maintains a prominent position in the field, actively engaging in advocacy efforts that have successfully influenced Congress to restore funding for lupus research. In April 2026, the LRA partnered with the Rheumatology Research Foundation to commit $1.9 million in grants to support early-career scientists advancing lupus research. Recent news highlights ongoing advancements in lupus treatments, including FDA approvals and applications for new therapies.

Latest updates

Lupus Research Alliance Highlights Progress Amidst Urgent Funding Needs

Event summary

  • The Lupus Research Alliance (LRA) is marking Lupus Awareness Month with initiatives focused on community engagement and fundraising.
  • LRA is the largest private funder of lupus research globally, with 100% of donations directly supporting research programs.
  • The organization reports promising advancements in lupus therapies and potential drug candidates.
  • A 'Walk with Us to Cure Lupus' event is scheduled for May 9th in New Jersey, aiming to raise funds and foster community.

The big picture

Lupus, a chronic autoimmune disease affecting millions globally, demands significant research investment. The Lupus Research Alliance's position as the largest private funder underscores the unmet need and the reliance on philanthropic support. The organization's focus on community engagement and highlighting progress signals an effort to maintain donor interest and accelerate research timelines in a competitive healthcare landscape.

What we're watching

Funding Sustainability
The LRA's reliance on private funding makes its progress vulnerable to economic shifts and donor priorities; sustained momentum requires diversification of funding sources.
Clinical Translation
While promising therapies are emerging, the pace at which these breakthroughs translate into widely accessible treatments for lupus patients will be a key indicator of long-term impact.
Community Engagement
The LRA's success hinges on maintaining strong community ties and advocacy; the effectiveness of initiatives like the 'Hope in Action' wall and virtual fireside chat will influence future participation.

Lupus Research Alliance Funds Novel Approaches to Autoimmune Disease

Event summary

  • The Lupus Research Alliance (LRA) awarded six Lupus Innovation Awards, totaling up to $150,000 per year for two years per recipient.
  • The awards support projects focused on improving lupus diagnosis and treatment through novel research approaches.
  • Recipients include researchers from Icahn School of Medicine at Mount Sinai, Emory University, Johns Hopkins Medicine, Sloan Kettering Institute, University of Michigan, and University of Washington.
  • One award supports an early-stage investigator, who is eligible for an additional year of funding.
  • Research areas include viral triggers, T cell function, kidney cell behavior, TLR7 signaling, antiphospholipid syndrome, and skin inflammation.

The big picture

The Lupus Research Alliance's continued investment in high-risk, high-reward research underscores the ongoing need for innovative approaches to treating lupus, a disease with limited therapeutic options and a significant unmet need. The focus on early-stage investigators and novel mechanisms reflects a strategic shift towards more targeted and potentially curative therapies, rather than solely managing symptoms. This funding model, with 100% of donations going to research, positions the LRA as a key driver in the lupus research landscape.

What we're watching

Viral Exposure
Dr. Asgari’s research into viral triggers could reveal new preventative strategies, but the complexity of viral interactions with the immune system may prove challenging to translate into actionable therapies.
Clinical Translation
The success of these projects hinges on the ability to translate findings from mouse models and in-vitro studies into effective treatments for human lupus patients, a historically difficult hurdle.
Biomarker Validation
Dr. Fava’s work on urine biomarkers for kidney damage requires rigorous validation to ensure clinical utility and avoid false positives or negatives that could impact patient management.

Lupus Research Alliance Funds Global Training Program to Address Specialist Shortage

Event summary

  • The Lupus Research Alliance (LRA) is funding the 2026-2027 SLEuro Mentorship Program, an 8-week training initiative for young physicians.
  • Twenty recipients from 16 countries across Europe, Asia, Central America, and North America have been selected for the program.
  • The program aims to address the global shortage of lupus specialists and researchers.
  • LRA, the world’s largest private funder of lupus research, covers all administrative and fundraising costs, ensuring 100% of donations go to research.

The big picture

The Lupus Research Alliance's investment in this mentorship program highlights the growing recognition of the need for specialized expertise in treating lupus, a complex and underserved autoimmune disease. The program's global scope reflects the disease's worldwide prevalence and the challenges in accessing quality care. By fostering a network of trained specialists, LRA is strategically addressing a critical bottleneck in lupus research and patient outcomes.

What we're watching

Program Impact
The long-term success of the program will depend on whether participants implement the learned skills and projects within their home institutions, ultimately contributing to improved lupus care and research outcomes.
Funding Sustainability
Continued funding from LRA and potential expansion to other regions will be critical for the program's longevity and ability to address the global specialist shortage.
Collaboration Scope
The extent to which this mentorship program expands the broader scientific collaboration between LRA and SLEuro will indicate the potential for future joint initiatives and knowledge sharing.
CID: 1652